Oncomed Pharmaceuticals Company Profile (NASDAQ:OMED)

About Oncomed Pharmaceuticals (NASDAQ:OMED)

Oncomed Pharmaceuticals logoOncoMed Pharmaceuticals, Inc. (OncoMed) is a clinical-stage biopharmaceutical company. The Company focuses on discovering and developing therapeutics that address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. The Company's therapeutic candidates and preclinical programs include Demcizumab (Anti-DLL4, OMP-21M18), Tarextumab (Anti-Notch2/3, OMP-59R5), Vantictumab (anti-Fzd7, OMP-18R5), Ipafricept (Fzd8-Fc, OMP-54F28), Brontictuzumab (Anti-Notch1, OMP-52M51), Navicixizumab (Anti-DLL4/VEGF Bispecific, OMP-305B83), Anti-RSPO3 (OMP-131R10), Anti-TIGIT (OMP-313M32) and GITRL-Fc trimer (OMP-336B11). Demcizumab is a humanized monoclonal antibody that inhibits Delta-like Ligand 4 (DLL4) in the Notch signaling pathway. Tarextumab is a human monoclonal antibody that binds to both the Notch2 and Notch3 receptors.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biotechnology
  • Sub-Industry: N/A
  • Symbol: NASDAQ:OMED
  • CUSIP: N/A
  • Web: www.oncomed.com
Capitalization:
  • Market Cap: $138.45 million
  • Outstanding Shares: 37,623,000
Average Prices:
  • 50 Day Moving Avg: $4.03
  • 200 Day Moving Avg: $7.53
  • 52 Week Range: $3.25 - $15.35
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -2.26
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: $25.02 million
  • Price / Sales: 5.53
  • Book Value: ($1.08) per share
  • Price / Book: -3.41
Profitability:
  • EBIDTA: ($97,140,000.00)
  • Net Margins: -409.54%
  • Return on Equity: -1,307.23%
  • Return on Assets: -17.68%
Debt:
  • Current Ratio: 3.83%
  • Quick Ratio: 3.83%
Misc:
  • Average Volume: 507,266 shs.
  • Beta: 2.81
  • Short Ratio: 10.5
 

Frequently Asked Questions for Oncomed Pharmaceuticals (NASDAQ:OMED)

What is Oncomed Pharmaceuticals' stock symbol?

Oncomed Pharmaceuticals trades on the NASDAQ under the ticker symbol "OMED."

How were Oncomed Pharmaceuticals' earnings last quarter?

Oncomed Pharmaceuticals Inc (NASDAQ:OMED) issued its earnings results on Monday, May, 8th. The company reported ($0.61) EPS for the quarter, topping the consensus estimate of ($0.62) by $0.01. The company had revenue of $6.20 million for the quarter, compared to the consensus estimate of $5.85 million. Oncomed Pharmaceuticals had a negative net margin of 409.54% and a negative return on equity of 1,307.23%. The firm's revenue for the quarter was down 2.4% on a year-over-year basis. During the same period in the previous year, the firm earned ($0.90) earnings per share. View Oncomed Pharmaceuticals' Earnings History.

Where is Oncomed Pharmaceuticals' stock going? Where will Oncomed Pharmaceuticals' stock price be in 2017?

9 brokerages have issued 1-year price objectives for Oncomed Pharmaceuticals' shares. Their predictions range from $5.00 to $40.00. On average, they anticipate Oncomed Pharmaceuticals' share price to reach $12.38 in the next twelve months. View Analyst Ratings for Oncomed Pharmaceuticals.

What are analysts saying about Oncomed Pharmaceuticals stock?

Here are some recent quotes from research analysts about Oncomed Pharmaceuticals stock:

  • 1. Cantor Fitzgerald analysts commented, "Restructuring plan should lengthen cash runway by at least a year, and we view a focus on assets with potential milestone opportunities as a positive given." (4/25/2017)
  • 2. According to Zacks Investment Research, "OncoMed Pharmaceuticals, Inc. is a biopharmaceutical company which focuses on the discovering and developing monoclonal antibody therapeutics for cancer stem cells. It utilizes its technologies to identify, isolate and evaluate CSCs, validate multiple potential targets and pathways critical to CSC self-renewal and differentiation and develop antibody and other protein-based therapeutics. The company serves the healthcare industry and cancer therapy patients. OncoMed Pharmaceuticals, Inc. is based in Redwood City, United States. " (4/13/2017)
  • 3. HC Wainwright analysts commented, "We believe a positive readout from the Phase 2 YOSEMITE trial in pancreatic cancer could lead partner Celgene to opt-in to the demcizumab program in early 2017, followed by readout from the Phase 2 DENALI trial in NSCLC a year later," analyst Shaunak Deepak wrote in a note.Related Link: Shkreli Warned You: Mast Therapeutics Plummets 80% After Sickle Cell Drug Phase 3 Trial FailMeanwhile, the upcoming data of vantictumab in breast cancer patients could drive Bayer's opt-in to the Wnt program in 2017."We regard the pancreatic cancer indication as a source of potential upside for our vantictumab estimates. We see the second Wnt pathway antagonist ipafricept as a source of potential upside," Deepak highlighted.Further, the analyst expects GlaxoSmithKline may opt-in to develop tarextumab, as it may show activity in lung cancer despite the compound failed in pancreatic cancer trial."In addition to near-term opt-in milestones that could reach $172 million, we believe these partnerships could payoff with long-term benefits and free-up OncoMed's resources to pursue new development activities," (9/22/2016)

Who are some of Oncomed Pharmaceuticals' key competitors?

Who owns Oncomed Pharmaceuticals stock?

Oncomed Pharmaceuticals' stock is owned by many different of institutional and retail investors. Top institutional investors include Primecap Management Co. CA (5.10%), FMR LLC (2.64%), Vanguard Group Inc. (2.53%), Ameriprise Financial Inc. (1.82%), Renaissance Technologies LLC (1.43%) and Candriam Luxembourg S.C.A. (0.57%). Company insiders that own Oncomed Pharmaceuticals stock include Alicia J Hager, Austin Gurney, Jack W Lasersohn, Jakob Dupont, John A Lewicki, Jonathan D Root, Paul J Hastings, Sunil Patel and Timothy Hoey. View Institutional Ownership Trends for Oncomed Pharmaceuticals.

Who sold Oncomed Pharmaceuticals stock? Who is selling Oncomed Pharmaceuticals stock?

Oncomed Pharmaceuticals' stock was sold by a variety of institutional investors in the last quarter, including First Eagle Investment Management LLC, Morgan Stanley, Birchview Capital LP, NJ State Employees Deferred Compensation Plan, FMR LLC, Credit Suisse AG, TIAA CREF Investment Management LLC and ProShare Advisors LLC. Company insiders that have sold Oncomed Pharmaceuticals stock in the last year include Alicia J Hager, John A Lewicki, Jonathan D Root, Paul J Hastings, Sunil Patel and Timothy Hoey. View Insider Buying and Selling for Oncomed Pharmaceuticals.

Who bought Oncomed Pharmaceuticals stock? Who is buying Oncomed Pharmaceuticals stock?

Oncomed Pharmaceuticals' stock was acquired by a variety of institutional investors in the last quarter, including Ameriprise Financial Inc., Primecap Management Co. CA, Renaissance Technologies LLC, Piermont Capital Management Inc., Granite Investment Partners LLC, Vanguard Group Inc., SG Americas Securities LLC and Trexquant Investment LP. View Insider Buying and Selling for Oncomed Pharmaceuticals.

How do I buy Oncomed Pharmaceuticals stock?

Shares of Oncomed Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of Oncomed Pharmaceuticals stock cost?

One share of Oncomed Pharmaceuticals stock can currently be purchased for approximately $3.68.


MarketBeat Community Rating for Oncomed Pharmaceuticals (NASDAQ:OMED)
Community Ranking:  2.8 out of 5 ( )
Outperform Votes:  129 (Vote Outperform)
Underperform Votes:  99 (Vote Underperform)
Total Votes:  228
These ratings are a survey of what our community members think about Oncomed Pharmaceuticals. An outperform vote indicates that you believe the stock will outperform the S&P 500 over the long term. An underperform vote indicates that you believe the stock will underperform the S&P 500.

Analyst Ratings

Consensus Ratings for Oncomed Pharmaceuticals (NASDAQ:OMED) (?)
Ratings Breakdown: 7 Hold Ratings, 2 Buy Ratings
Consensus Rating:Hold (Score: 2.22)
Consensus Price Target: $12.38 (236.28% upside)

Analysts' Ratings History for Oncomed Pharmaceuticals (NASDAQ:OMED)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
5/15/2017HC WainwrightLower Price TargetBuy -> Buy$9.00 -> $6.00LowView Rating Details
5/9/2017Cantor FitzgeraldSet Price TargetHold$6.00HighView Rating Details
4/17/2017JMP SecuritiesDowngradeOutperform -> Market PerformLowView Rating Details
4/17/2017SunTrust Banks, Inc.DowngradeBuy -> HoldHighView Rating Details
4/17/2017Piper Jaffray CompaniesDowngradeOverweight -> Neutral$17.00 -> $5.00HighView Rating Details
4/11/2017Jefferies Group LLCReiterated RatingBuy$15.00 -> $10.00HighView Rating Details
4/11/2017Leerink SwannBoost Price TargetMarket Perform$6.00 -> $10.00HighView Rating Details
4/11/2017BMO Capital MarketsDowngradeOutperform -> Market Perform$6.00HighView Rating Details
6/1/2016MizuhoLower Price TargetNeutral$45.00 -> $40.00N/AView Rating Details
12/3/2015Wells Fargo & CoInitiated CoverageOutperformN/AView Rating Details
(Data available from 5/28/2015 forward)

Earnings

Earnings History for Oncomed Pharmaceuticals (NASDAQ:OMED)
Earnings by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)
Earnings History by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
5/8/2017Q1 2017($0.62)($0.61)$5.85 million$6.20 millionViewListenView Earnings Details
3/8/2017Q4 2016($0.68)($0.60)$6.57 million$6.22 millionViewListenView Earnings Details
11/1/2016Q3($0.77)($0.77)$9.48 million$5.92 millionViewN/AView Earnings Details
8/9/2016Q216($0.81)($0.91)$8.09 million$6.67 millionViewN/AView Earnings Details
5/5/2016Q1($0.73)($0.90)$8.28 million$6.40 millionViewN/AView Earnings Details
3/10/2016Q4$0.41$1.50$44.55 million$6.80 millionViewListenView Earnings Details
11/5/2015Q315($0.80)($0.81)$5.84 million$4.70 millionViewListenView Earnings Details
8/10/2015Q215($0.49)($0.72)$13.78 million$4.70 millionViewListenView Earnings Details
5/7/2015Q115($0.35)($0.49)$15.35 million$9.70 millionViewN/AView Earnings Details
3/12/2015Q414($0.27)($0.50)$11.92 million$8.51 millionViewN/AView Earnings Details
11/4/2014($0.30)($0.18)$17.84 million$19.02 millionViewN/AView Earnings Details
8/7/2014Q214($0.03)($0.53)$21.28 million$6.00 millionViewN/AView Earnings Details
5/8/2014Q114($0.13)($0.47)$18.08 million$6.02 millionViewN/AView Earnings Details
3/18/2014Q4 13$0.15($0.15)$20.37 million$19.00 millionViewN/AView Earnings Details
11/12/2013Q3$0.12($0.15)ViewN/AView Earnings Details
9/3/2013Q2 2013($0.02)($0.83)$8.31 million$2.90 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Oncomed Pharmaceuticals (NASDAQ:OMED)
2017 EPS Consensus Estimate: ($1.94)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20173($0.76)($0.63)($0.68)
Q2 20173($0.65)($0.37)($0.47)
Q3 20173($0.56)($0.29)($0.41)
Q4 20173($0.49)($0.29)($0.38)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Oncomed Pharmaceuticals (NASDAQ:OMED)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Oncomed Pharmaceuticals (NASDAQ:OMED)
Insider Ownership Percentage: 41.25%
Institutional Ownership Percentage: 42.24%
Insider Trades by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)
Institutional Ownership by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)
Insider Trades by Quarter for Oncomed Pharmaceuticals (NASDAQ:OMED)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
5/26/2017Jonathan D RootDirectorSell13,880$3.71$51,494.80View SEC Filing  
5/25/2017Jack W LasersohnDirectorBuy34,614$3.37$116,649.18View SEC Filing  
5/23/2017Jack W LasersohnDirectorBuy20,000$3.55$71,000.00View SEC Filing  
5/19/2017Jonathan D RootDirectorSell7,487$3.70$27,701.90View SEC Filing  
5/16/2017Jack W LasersohnDirectorBuy23,507$3.49$82,039.43View SEC Filing  
4/4/2017Alicia J. HagerSVPSell4,316$9.06$39,102.96View SEC Filing  
4/4/2017Paul J. HastingsCEOSell6,473$9.06$58,645.38View SEC Filing  
4/4/2017Sunil PatelInsiderSell5,754$9.06$52,131.24View SEC Filing  
1/6/2017Paul J. HastingsCEOSell42,738$8.34$356,434.92View SEC Filing  
1/3/2017John A. LewickiEVPSell9,175$7.63$70,005.25View SEC Filing  
1/3/2017Timothy HoeySVPSell12,763$7.64$97,509.32View SEC Filing  
1/11/2016Jakob DupontSVPSell2,500$20.01$50,025.00View SEC Filing  
1/7/2016Alicia J. HagerVPSell1,623$22.28$36,160.44View SEC Filing  
1/7/2016John A. LewickiEVPSell2,162$22.28$48,169.36View SEC Filing  
1/6/2016Paul J. HastingsCEOSell2,412$22.28$53,739.36View SEC Filing  
11/27/2015Alicia J. HagerVPSell1,800$23.14$41,652.00View SEC Filing  
10/27/2015Alicia J. HagerVPSell5,400$21.00$113,400.00View SEC Filing  
10/26/2015Austin GurneyInsiderSell14,000$20.00$280,000.00View SEC Filing  
10/26/2015Jakob DupontSVPSell5,000$20.00$100,000.00View SEC Filing  
9/30/2015Jack W. LasersohnDirectorBuy11,210$16.01$179,472.10View SEC Filing  
9/29/2015Jack W. LasersohnDirectorBuy3,140$14.15$44,431.00View SEC Filing  
9/28/2015Jack W. LasersohnDirectorBuy10,000$14.74$147,400.00View SEC Filing  
7/10/2015Jakob DupontSVPSell2,500$20.13$50,325.00View SEC Filing  
7/6/2015Jakob DupontSVPSell2,500$21.22$53,050.00View SEC Filing  
6/29/2015Alicia J HagerVPSell1,800$22.67$40,806.00View SEC Filing  
6/22/2015Timothy HoeySVPSell5,000$26.07$130,350.00View SEC Filing  
6/16/2015John A LewickiEVPSell17,000$25.07$426,190.00View SEC Filing  
6/15/2015John A LewickiEVPSell8,500$24.92$211,820.00View SEC Filing  
5/27/2015Alicia J HagerVPSell1,800$23.07$41,526.00View SEC Filing  
5/18/2015Austin GurneyInsiderSell4,000$22.48$89,920.00View SEC Filing  
4/27/2015Alicia J HagerVPSell1,800$25.65$46,170.00View SEC Filing  
4/27/2015Timothy HoeySVPSell6,887$25.65$176,651.55View SEC Filing  
4/17/2015Austin GurneyInsiderSell4,000$25.51$102,040.00View SEC Filing  
4/10/2015Jakob DupontSVPSell1,500$26.51$39,765.00View SEC Filing  
4/2/2015John A LewickiEVPSell17,000$25.28$429,760.00View SEC Filing  
3/20/2015Sunil PatelInsiderSell18,000$27.76$499,680.00View SEC Filing  
3/17/2015Austin GurneyInsiderSell4,000$27.37$109,480.00View SEC Filing  
2/5/2015Timothy HoeySVPSell7,500$22.83$171,225.00View SEC Filing  
2/2/2015John A LewickiEVPSell4,000$22.49$89,960.00View SEC Filing  
1/20/2015Austin GurneyInsiderSell4,000$22.87$91,480.00View SEC Filing  
1/12/2015Jakob DupontSVPSell1,500$25.89$38,835.00View SEC Filing  
1/5/2015Jakob DupontSVPSell7,500$23.00$172,500.00View SEC Filing  
1/2/2015John A LewickiEVPSell4,000$22.10$88,400.00View SEC Filing  
12/31/2014Denise Pollard-KnightDirectorSell3,799$21.66$82,286.34View SEC Filing  
12/30/2014Denise Pollard-KnightDirectorSell17,607$21.63$380,839.41View SEC Filing  
12/18/2014Jonathan D RootDirectorSell13,052$21.05$274,744.60View SEC Filing  
12/17/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
12/10/2014Denise Pollard-KnightDirectorSell32,940$21.78$717,433.20View SEC Filing  
12/9/2014Denise Pollard-KnightDirectorSell23,273$21.78$506,885.94View SEC Filing  
12/8/2014Denise Pollard-KnightDirectorSell1,727$21.68$37,441.36View SEC Filing  
12/5/2014Denise Pollard-KnightDirectorSell25,000$21.60$540,000.00View SEC Filing  
12/1/2014John A LewickiEVPSell4,000$21.19$84,760.00View SEC Filing  
11/5/2014Timothy HoeySVPSell2,500$19.51$48,775.00View SEC Filing  
10/29/2014Paul J HastingsCEOSell16,769$21.99$368,750.31View SEC Filing  
10/2/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
10/2/2014John A LewickiEVPSell5,809$20.00$116,180.00View SEC Filing  
9/4/2014Jack W LasersohnDirectorBuy3,170$18.35$58,169.50View SEC Filing  
9/3/2014Jack W LasersohnDirectorBuy3,000$18.40$55,200.00View SEC Filing  
9/2/2014John A LewickiEVPSell2,191$20.01$43,841.91View SEC Filing  
8/22/2014Austin GurneyInsiderSell4,000$20.00$80,000.00View SEC Filing  
8/21/2014Deepika PakianathanDirectorBuy80,203$18.98$1,522,252.94View SEC Filing  
8/15/2014Jack W LasersohnDirectorBuy1,045$17.00$17,765.00View SEC Filing  
8/5/2014Timothy HoeySVPSell2,500$21.66$54,150.00View SEC Filing  
8/1/2014John A LewickiEVPSell4,000$20.98$83,920.00View SEC Filing  
7/29/2014Paul J HastingsCEOSell16,770$22.11$370,784.70View SEC Filing  
7/23/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
7/17/2014Austin GurneyInsiderSell4,000$20.46$81,840.00View SEC Filing  
7/1/2014John A LewickiEVPSell4,000$23.86$95,440.00View SEC Filing  
6/30/2014Denise Pollard-KnightDirectorSell11,485$23.59$270,931.15View SEC Filing  
6/26/2014Jakob DupontSVPSell1,500$23.00$34,500.00View SEC Filing  
6/25/2014Denise Pollard-KnightDirectorSell3,252$23.56$76,617.12View SEC Filing  
6/24/2014Denise Pollard-KnightDirectorSell64,561$24.08$1,554,628.88View SEC Filing  
6/17/2014Austin GurneyInsiderSell4,000$24.99$99,960.00View SEC Filing  
6/16/2014John A LewickiEVPSell4,000$24.59$98,360.00View SEC Filing  
6/10/2014Presidio Management Group ViiiMajor ShareholderSell13,052$24.57$320,687.64View SEC Filing  
5/12/2014Presidio Management Group Viiimajor shareholderSell46,327$21.99$1,018,730.73View SEC Filing  
7/23/2013Denise Pollard-KnightDirectorBuy58,824$17.00$1,000,008.00View SEC Filing  
7/23/2013Presidio Management Group ViiiMajor ShareholderBuy158,823$17.00$2,699,991.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Oncomed Pharmaceuticals (NASDAQ:OMED)
Latest Headlines for Oncomed Pharmaceuticals (NASDAQ:OMED)
Source:
DateHeadline
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Director Jack W. Lasersohn Acquires 34,614 Shares
www.americanbankingnews.com - May 26 at 8:02 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Director Jonathan D. Root Sells 13,880 Shares
www.americanbankingnews.com - May 26 at 1:51 PM
seekingalpha.com logoIs OncoMed A Contrarian Buy?
seekingalpha.com - May 26 at 5:31 AM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Director Acquires $71,000.00 in Stock
www.americanbankingnews.com - May 25 at 8:29 PM
americanbankingnews.com logoJonathan D. Root Sells 7,487 Shares of Oncomed Pharmaceuticals Inc (OMED) Stock
www.americanbankingnews.com - May 22 at 10:28 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Director Acquires $82,039.43 in Stock
www.americanbankingnews.com - May 18 at 8:11 PM
businesswire.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc. - Business Wire (press release)
www.businesswire.com - May 16 at 10:04 AM
finance.yahoo.com logoNewman Ferrara LLP Announces Corporate Governance Investigation of OncoMed Pharmaceuticals Inc.
finance.yahoo.com - May 16 at 10:04 AM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Price Target Lowered to $6.00 at HC Wainwright
www.americanbankingnews.com - May 15 at 10:12 AM
finance.yahoo.com logoEdited Transcript of OMED earnings conference call or presentation 8-May-17 12:30pm GMT
finance.yahoo.com - May 13 at 12:48 AM
americanbankingnews.com logoFY2017 Earnings Forecast for Oncomed Pharmaceuticals Inc (OMED) Issued By Cantor Fitzgerald
www.americanbankingnews.com - May 12 at 12:32 PM
americanbankingnews.com logoBrokers Offer Predictions for Oncomed Pharmaceuticals Inc's Q2 2017 Earnings (OMED)
www.americanbankingnews.com - May 12 at 8:51 AM
americanbankingnews.com logo Analysts Expect Oncomed Pharmaceuticals Inc (OMED) Will Announce Earnings of -$0.43 Per Share
www.americanbankingnews.com - May 11 at 8:20 PM
finance.yahoo.com logoHuman Antibody Discovery: Of Mice And Phage
finance.yahoo.com - May 11 at 9:06 AM
americanbankingnews.com logoJefferies Group Comments on Oncomed Pharmaceuticals Inc's Q2 2017 Earnings (OMED)
www.americanbankingnews.com - May 11 at 7:56 AM
americanbankingnews.com logoOncomed Pharmaceuticals Inc Forecasted to Earn Q2 2017 Earnings of ($0.37) Per Share (OMED)
www.americanbankingnews.com - May 11 at 7:56 AM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Given a $6.00 Price Target at Cantor Fitzgerald
www.americanbankingnews.com - May 9 at 11:02 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Posts Earnings Results, Beats Estimates By $0.01 EPS
www.americanbankingnews.com - May 8 at 9:24 PM
finance.yahoo.com logoOncoMed reports 1Q loss
finance.yahoo.com - May 8 at 12:11 PM
finance.yahoo.com logoInvestor Network: OncoMed Pharmaceuticals, Inc. to Host Earnings Call
finance.yahoo.com - May 8 at 12:11 PM
finance.yahoo.com logoOncoMed Pharma stock drops 17% after clinical trial miss; Q1 revenue miss
finance.yahoo.com - May 8 at 12:11 PM
finance.yahoo.com logoOncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial - Yahoo Finance
finance.yahoo.com - May 5 at 12:13 AM
globenewswire.com logoOncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017 - GlobeNewswire (press release)
globenewswire.com - May 5 at 12:13 AM
reuters.com logoBRIEF-Oncomed doses first patient with anti-tigit antibody in phase 1 clinical trial
www.reuters.com - May 4 at 7:11 PM
finance.yahoo.com logoOncoMed Doses First Patient with Anti-TIGIT Antibody in Phase 1 Clinical Trial
finance.yahoo.com - May 4 at 7:11 PM
americanbankingnews.com logoOncomed Pharmaceuticals (OMED) Given Media Sentiment Rating of 0.25
www.americanbankingnews.com - May 4 at 1:10 AM
finance.yahoo.com logoOncoMed Pharmaceuticals to Report First Quarter Financial Results on May 8th, 2017
finance.yahoo.com - May 3 at 8:01 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Given Average Rating of "Hold" by Brokerages
www.americanbankingnews.com - May 2 at 10:04 AM
americanbankingnews.com logoOncomed Pharmaceuticals (OMED) Earning Very Positive News Coverage, Study Shows
www.americanbankingnews.com - April 30 at 10:22 AM
americanbankingnews.com logo-$0.62 Earnings Per Share Expected for Oncomed Pharmaceuticals Inc (OMED) This Quarter
www.americanbankingnews.com - April 28 at 1:03 AM
reuters.com logoBRIEF-BVF Partners reports 7.9 pct passive stake in Oncomed Pharmaceuticals as of April 17
www.reuters.com - April 27 at 7:31 PM
rttnews.com logoOncoMed Pharma To Reduce Its Workforce By About 50%
www.rttnews.com - April 25 at 11:42 AM
reuters.com logoBRIEF-Oncomed reports workforce reduction
www.reuters.com - April 25 at 11:42 AM
finance.yahoo.com logoOncoMed to lay off half of its staff
finance.yahoo.com - April 25 at 11:41 AM
finance.yahoo.com logoBay Area biotech slashes half of staff after drug partnerships falter
finance.yahoo.com - April 25 at 11:41 AM
finance.yahoo.com logoOncoMed Announces Workforce Reduction
finance.yahoo.com - April 24 at 4:43 PM
americanbankingnews.com logoOncomed Pharmaceuticals (OMED) Getting Somewhat Critical Media Coverage, Report Finds
www.americanbankingnews.com - April 24 at 2:06 PM
americanbankingnews.com logoOncomed Pharmaceuticals (OMED) Earning Somewhat Positive News Coverage, Study Shows
www.americanbankingnews.com - April 22 at 12:59 AM
americanbankingnews.com logoShort Interest in Oncomed Pharmaceuticals Inc (OMED) Declines By 13.3%
www.americanbankingnews.com - April 21 at 10:58 AM
americanbankingnews.com logo Brokerages Expect Oncomed Pharmaceuticals Inc (OMED) Will Announce Earnings of -$0.62 Per Share
www.americanbankingnews.com - April 21 at 12:11 AM
marketwatch.com logoOncoMed is having a no good, very bad week - MarketWatch - MarketWatch
www.marketwatch.com - April 19 at 10:06 AM
finance.yahoo.com logoHere's Why OncoMed Pharmaceuticals (OMED) Stock Fell Today - Yahoo Finance
finance.yahoo.com - April 19 at 10:06 AM
finance.yahoo.com logoHere's Why OncoMed Pharmaceuticals (OMED) Stock Fell Today
finance.yahoo.com - April 19 at 10:06 AM
americanbankingnews.com logoQ2 2017 EPS Estimates for Oncomed Pharmaceuticals Inc Raised by Analyst (OMED)
www.americanbankingnews.com - April 19 at 8:35 AM
americanbankingnews.com logoOncomed Pharmaceuticals (OMED) Receives Media Impact Score of 0.11
www.americanbankingnews.com - April 18 at 8:53 PM
zacks.com logoHere's Why OncoMed Pharmaceuticals (OMED) Stock Fell Today
www.zacks.com - April 18 at 6:21 PM
nasdaq.com logoOncoMed's Phase 2 Trial Of Tarextumab In SCLC Fails To Meet Endpoints
www.nasdaq.com - April 17 at 6:12 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Stock Rating Lowered by JMP Securities
www.americanbankingnews.com - April 17 at 4:39 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Downgraded by SunTrust Banks, Inc.
www.americanbankingnews.com - April 17 at 2:18 PM
americanbankingnews.com logoOncomed Pharmaceuticals Inc (OMED) Stock Rating Lowered by Piper Jaffray Companies
www.americanbankingnews.com - April 17 at 12:58 PM

Social

Chart

Oncomed Pharmaceuticals (OMED) Chart for Sunday, May, 28, 2017

This page was last updated on 5/28/2017 by MarketBeat.com Staff